<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03733678</url>
  </required_header>
  <id_info>
    <org_study_id>LARCs-2018</org_study_id>
    <nct_id>NCT03733678</nct_id>
  </id_info>
  <brief_title>A Randomized-Controlled Trial to Increase the Uptake of LARCs in Cameroon</brief_title>
  <acronym>HGOPY</acronym>
  <official_title>A Sequential and Adaptive Experiment to Increase the Uptake of Long-acting Reversible Contraceptives in Cameroon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>World Bank</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Exeter</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yaounde Gynecology, Obstetrics and Pediatrics Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>World Bank</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cameroon exhibits a high and non-decreasing level of maternal mortality (roughly 600 per
      100,000 live births), partially related to its relatively high total fertility rate (roughly
      4.6). Survey evidence furthermore suggests that a significant fraction of these pregnancies
      is unwanted or considered mistimed by the mother, especially among females aged 15-19.
      Despite this, the rate of utilization of family planning (FP) is low: e.g. only 48% of
      sexually active unmarried women use any form of (modern) contraception, or MC, and even then,
      it is primarily condoms. The use of LARCs (long-acting reversible contraceptives, i.e. the
      IUD and implant) is less than 1% according to the most recent Demographic Health Survey.

      The study investigators propose to use an integrated behavioral science approach to increase
      the take-up of both SARCs (short-acting reversible contraceptives, i.e. the pill and
      injectable) and especially LARCs among reproductive-age females in Cameroon, including
      adolescents who may be unmarried and/or nulliparous. In addition to decreasing maternal
      mortality and undesired pregnancies, indirect effects for the community will include:
      increased welfare from reduced side effects that arise due to current one-size-fits-all FP
      counseling; healthier children due to improved birth spacing; and increased human capital
      formation both for children and for young (often school-aged) potential mothers.

      The study investigators propose to conduct the study at HGOPY for a duration of 12 months.
      The study investigators will provide tablets to each of five nurses that conduct FP
      counseling to participants at the hospital. The tablets contain a counseling &quot;app&quot; (or
      decision-support tool or a job-aid) that was jointly developed by professionals from HGOPY,
      the World Bank, and the Ministry of Health. The study investigators propose an
      individually-randomized experiment, where the participants will be offered randomly varying
      discounts for the modern contraceptive methods they wish to adopt. The study investigators
      also propose to experiment with certain aspects of the &quot;app&quot; to improve its effectiveness -
      both for the participant and for the nurse. More details on the experimental design are
      provided below.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study independently experiments with two aspects of the health provider-client relationship:
First, a tablet-based counseling app that is used by the provider gives random discounts to clients - separately for LARCs and SARCs.
Second, the tablet-based app presents recommendations to the client sequentially (i.e. the top-ranked method, followed by the next one if that recommendation is declined by the client, etc.) vs. simultaneously (i.e. presenting the top recommendations to the client all at once and asking her to choose which one to discuss further).</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants are masked in some interventions related to the workings of the tablet-based decision-support tool, but not to the price discounts they receive for the contraceptive methods.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The client adopted a LARC</measure>
    <time_frame>1-day</time_frame>
    <description>using data from the counseling sessions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The client adopted a modern contraceptive method (LARC or SARC)</measure>
    <time_frame>1-day</time_frame>
    <description>using data from the counseling sessions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Was the client treated with respect by the provider during the counseling session?</measure>
    <time_frame>2-weeks</time_frame>
    <description>Self-reported indicator variable using follow-up surveys two weeks after counseling session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Did the client trust the provider during the counseling session?</measure>
    <time_frame>2-weeks</time_frame>
    <description>Self-reported indicator variable using follow-up surveys two weeks after counseling session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Did the health provider give information about contraceptive methods that was easy to understand during the counseling session?</measure>
    <time_frame>2-weeks</time_frame>
    <description>Self-reported indicator variable using follow-up surveys two weeks after counseling session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Client satisfaction with adopted contraceptive method</measure>
    <time_frame>2-week and 16-week measurements</time_frame>
    <description>using 2-week and 16-week follow-up surveys</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation of adopted contraceptive method</measure>
    <time_frame>2-week, 16-week, and 52-week measurements</time_frame>
    <description>using 2-week, 16-week, and 52-week follow-up surveys</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with unintended pregnancy within the time frame</measure>
    <time_frame>16-week and 52-week measurements</time_frame>
    <description>using 16-week and 52-week follow-up surveys</description>
  </secondary_outcome>
  <number_of_arms>20</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Contraception</condition>
  <condition>Contraception Behavior</condition>
  <condition>Contraceptive Usage</condition>
  <condition>Contraceptive Method Switching</condition>
  <arm_group>
    <arm_group_label>Free SARC, Free LARC, Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Free SARC, Free LARC, Sequential recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Free SARC, LARC=500, Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Free SARC, LARC=500 CFA, Sequential recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Free SARC, LARC=1000, Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Free SARC, LARC=1000 CFA, Sequential recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Free SARC, LARC=2140, Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Free SARC, LARC=2140 CFA, Sequential recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Free SARC, LARC=5000, Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Free SARC, LARC=5000 CFA, Sequential recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular SARC, Free LARC, Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regular price SARC, Free LARC, Sequential recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular SARC, LARC=500, Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regular price SARC, LARC=500 CFA, Sequential recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular SARC, LARC=1000, Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regular price SARC, LARC=1000 CFA, Sequential recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular SARC, LARC=2140, Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regular price SARC, LARC=2140 CFA, Sequential recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular SARC, LARC=5000, Recommendation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Regular price SARC, LARC=5000 CFA, Sequential recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Free SARC, Free LARC, No Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Free SARC, Free LARC, Simultaneous recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Free SARC, LARC=500, No Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Free SARC, LARC=500 CFA, Simultaneous recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Free SARC, LARC=1000, No Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Free SARC, LARC=1000 CFA, Simultaneous recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Free SARC, LARC=2140, No Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Free SARC, LARC=2140 CFA, Simultaneous recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Free SARC, LARC=5000, No Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Free SARC, LARC=5000 CFA, Simultaneous recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular SARC, Free LARC, No Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regular Price SARC, Free LARC, Simultaneous recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular SARC, LARC=500, No Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regular Price SARC, LARC=500 CFA, Simultaneous recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular SARC, LARC=1000, No Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regular Price SARC, LARC=1000 CFA, Simultaneous recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular SARC, LARC=2140, No Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regular Price SARC, LARC=2140 CFA, Simultaneous recommendation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular SARC, LARC=5000, No Recommendation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regular Price SARC, LARC=5000 CFA, Simultaneous recommendation</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Price discounts for SARCs</intervention_name>
    <description>SARCs are offered free to the client</description>
    <arm_group_label>Free SARC, Free LARC, No Recommendation</arm_group_label>
    <arm_group_label>Free SARC, Free LARC, Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=1000, No Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=1000, Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=2140, No Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=2140, Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=500, No Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=500, Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=5000, No Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=5000, Recommendation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Price discounts for LARCs</intervention_name>
    <description>LARCs are offered at lower prices to the client</description>
    <arm_group_label>Free SARC, Free LARC, No Recommendation</arm_group_label>
    <arm_group_label>Free SARC, Free LARC, Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=1000, No Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=1000, Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=2140, No Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=2140, Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=500, No Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=500, Recommendation</arm_group_label>
    <arm_group_label>Regular SARC, Free LARC, No Recommendation</arm_group_label>
    <arm_group_label>Regular SARC, Free LARC, Recommendation</arm_group_label>
    <arm_group_label>Regular SARC, LARC=1000, No Recommendation</arm_group_label>
    <arm_group_label>Regular SARC, LARC=1000, Recommendation</arm_group_label>
    <arm_group_label>Regular SARC, LARC=2140, No Recommendation</arm_group_label>
    <arm_group_label>Regular SARC, LARC=2140, Recommendation</arm_group_label>
    <arm_group_label>Regular SARC, LARC=500, No Recommendation</arm_group_label>
    <arm_group_label>Regular SARC, LARC=500, Recommendation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sequential vs. simultaneous recommendations</intervention_name>
    <description>Top ranked methods are presented to the client sequentially or simultaneously</description>
    <arm_group_label>Free SARC, Free LARC, No Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=1000, No Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=2140, No Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=500, No Recommendation</arm_group_label>
    <arm_group_label>Free SARC, LARC=5000, No Recommendation</arm_group_label>
    <arm_group_label>Regular SARC, Free LARC, No Recommendation</arm_group_label>
    <arm_group_label>Regular SARC, LARC=1000, No Recommendation</arm_group_label>
    <arm_group_label>Regular SARC, LARC=2140, No Recommendation</arm_group_label>
    <arm_group_label>Regular SARC, LARC=500, No Recommendation</arm_group_label>
    <arm_group_label>Regular SARC, LARC=5000, No Recommendation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Ages 10-49

          -  Presenting at HGOPY seeking FP counseling/services

          -  HGOPY clients referred to the family planning unit for consultation

        Exclusion Criteria:

        * No exclusion criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berk Ozler, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>World Bank</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital gynéco-obstétrique et pédiatrique de Yaoundé (HGOPY)</name>
      <address>
        <city>Yaoundé</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>World Bank</investigator_affiliation>
    <investigator_full_name>Berk Ozler</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>adolescent sexual and reproductive health, maternal mortality, teen pregnancy, LARCs, family planning counseling</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We will likely share de-identified anonymous participant data publicly after the trial ends and our analyses are completed.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

